Who is sponsoring NCT00926952?

NCT00926952 is sponsored by Innovaderm Research Inc..

What condition does NCT00926952 study?

NCT00926952 studies Actinic Keratosis.

What drugs are being tested in NCT00926952?

Interventions: Methylaminolevulinate (Metvix, Metvixia), Photodynamic Therapy (Aktilite).

What is the status of NCT00926952?

NCT00926952 is currently COMPLETED.

Last reviewed 2011-09-01 · How we verify

Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses.

NCT00926952 Phase 3 COMPLETED Results posted

Actinic keratoses on the face are often numerous and widespread. The application of Methylaminolevulinate (MAL) on individual lesions followed by the application of a plastic film on each lesion is difficult and takes time for subjects with many actinic keratoses. The waiting period of 3 hours between MAL cream application and red light exposure is also long for patients. The goal of this study is to evaluate the safety and efficacy of photodynamic therapy (PDT) with MAL with a shorter cream application time (90 minutes) and when MAL is applied on the entire face without the plastic film.

Details

Lead sponsor	Innovaderm Research Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	20
Start date	2009-07
Completion	2011-01

Conditions

Actinic Keratosis

Interventions

Methylaminolevulinate (Metvix, Metvixia)
Photodynamic Therapy (Aktilite)

Primary outcomes

Mean Number of Facial Actinic Keratoses at Week 12 — 12 weeks

Countries

Canada